ADC Therapeutics is a biotechnology business based in the US. ADC Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. ADC Therapeutics employs 317 staff and has a trailing 12-month revenue of around $182.4 million.
How to buy ADC Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ADCT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 in stock when you fund a new account within 30 days
M1 Finance
- Commission-free stock and ETF trades
- No management fees
- Customizable portfolios with automatic rebalancing
ADC Therapeutics stock price (NYSE: ADCT)
Use our graph to track the performance of ADCT stocks over time.ADC Therapeutics shares at a glance
Latest market close | $2.49 |
---|---|
52-week range | $1.85 - $10.88 |
50-day moving average | $2.19 |
200-day moving average | $3.88 |
Wall St. target price | $10.67 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.54 |
Buy ADC Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy ADC Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ADC Therapeutics price performance over time
Historical closes compared with the close of $2.49 from 2023-06-02
1 week (2023-05-26) | 9.21% |
---|---|
1 month (2023-05-05) | 27.04% |
3 months (2023-03-03) | -20.70% |
6 months (2022-12-05) | -29.06% |
1 year (2022-06-03) | -65.42% |
---|---|
2 years (2021-06-04) | -88.68% |
3 years (2020-06-05) | 34.95 |
5 years (2018-06-01) | N/A |
ADC Therapeutics financials
Revenue TTM | $182.4 million |
---|---|
Gross profit TTM | $35.1 million |
Return on assets TTM | -16.03% |
Return on equity TTM | -198.22% |
Profit margin | -108.86% |
Book value | $0.47 |
Market capitalisation | $200.8 million |
TTM: trailing 12 months
ADC Therapeutics share dividends
We're not expecting ADC Therapeutics to pay a dividend over the next 12 months.
ADC Therapeutics share price volatility
Over the last 12 months, ADC Therapeutics's shares have ranged in value from as little as $1.85 up to $10.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ADC Therapeutics's is 1.1057. This would suggest that ADC Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ADC Therapeutics overview
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBD"dimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B. V. , Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited.
ADC Therapeutics in the news
Sobi to present new data at the 2023 EHA congress
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
Frequently asked questions
What percentage of ADC Therapeutics is owned by insiders or institutions?Currently 32.603% of ADC Therapeutics shares are held by insiders and 64.314% by institutions. How many people work for ADC Therapeutics?
Latest data suggests 317 work at ADC Therapeutics. When does the fiscal year end for ADC Therapeutics?
ADC Therapeutics's fiscal year ends in September. Where is ADC Therapeutics based?
ADC Therapeutics's address is: Biopole, Epalinges, Switzerland, 1066 What is ADC Therapeutics's ISIN number?
ADC Therapeutics's international securities identification number is: CH0499880968
More guides on Finder
-
JP Morgan Personal Advisors review 2023
Access remote advice, planning and portfolio management from this established financial services company.
-
How to buy Energy Transfer Equity stock
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
-
How to buy Uranium Energy stock
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
-
How to buy Gold Royalty stock
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
-
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
-
Best online brokers & platforms to buy gold stocks in June 2023
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
-
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
-
How to buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
-
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Ask an Expert